Isolation and Characterization of An Allergic Dimer Impurity in Cefmenoxime Hydrochloride by NMR and HR-MS Method / Jin Li, Shang-Chen Yao, Li-hui Yin, Chang-Qin Hu, Ming-Zhe Xu
Background: We systematically characterized an allergic dimer impurity in cefmenoxime hydrochloride raw material by UV, IR, HR-MS, 1D, and 2D NMR for the first time. Methods: The dimer stock solution of cefmenoxime hydrochloride was obtained by the degradation method. The target dimer impurity in the stock solution was separated by preparative RP-HPLC and purified by the freeze-drying method. By comparing the dimer to cefmenoxime hydrochloride, the functional groups corresponding to the characteristic peaks of UV and IR spectra were identified, and the molecular formula and mass fragmentation pattern were determined using HR-MS. Results: Then, based on the full assignment of 1 H and 13 C NMR signals, the dimerized position was confirmed and its absolute configuration was identified by 1D and 2D NMR. Conclusion: This study provided a structural basis for the allergic study of dimer impurities in cephalosporin drugs.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
---|---|
Enthalten in: |
Current pharmaceutical analysis - 18(2022), 7, Seite 9 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Jin [VerfasserIn] |
---|
Links: |
FID Access [lizenzpflichtig] |
---|
Umfang: |
1 Online-Ressource (9 p) |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
KFL011170638 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | KFL011170638 | ||
003 | DE-627 | ||
005 | 20231128145741.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230613s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)KFL011170638 | ||
035 | |a (KFL)prod_DARH_.EE97CAA79DED4D2EE63F937C0086D06928923DCF | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
084 | |a PHARM |q DE-84 |2 fid | ||
100 | 1 | |a Li, Jin |e verfasserin |4 aut | |
245 | 1 | 0 | |a Isolation and Characterization of An Allergic Dimer Impurity in Cefmenoxime Hydrochloride by NMR and HR-MS Method |c Jin Li, Shang-Chen Yao, Li-hui Yin, Chang-Qin Hu, Ming-Zhe Xu |
264 | 1 | |c 2022 | |
300 | |a 1 Online-Ressource (9 p) | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background: We systematically characterized an allergic dimer impurity in cefmenoxime hydrochloride raw material by UV, IR, HR-MS, 1D, and 2D NMR for the first time. Methods: The dimer stock solution of cefmenoxime hydrochloride was obtained by the degradation method. The target dimer impurity in the stock solution was separated by preparative RP-HPLC and purified by the freeze-drying method. By comparing the dimer to cefmenoxime hydrochloride, the functional groups corresponding to the characteristic peaks of UV and IR spectra were identified, and the molecular formula and mass fragmentation pattern were determined using HR-MS. Results: Then, based on the full assignment of 1 H and 13 C NMR signals, the dimerized position was confirmed and its absolute configuration was identified by 1D and 2D NMR. Conclusion: This study provided a structural basis for the allergic study of dimer impurities in cephalosporin drugs | ||
700 | 1 | |a Yao, Shang-Chen |e verfasserin |4 aut | |
700 | 1 | |a Yin, Li-hui |e verfasserin |4 aut | |
700 | 1 | |a Hu, Chang-Qin |e verfasserin |4 aut | |
700 | 1 | |a Xu, Ming-Zhe |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical analysis |d Sharjah, U.A.E. : Bentham Science Publ., 2005 |g 18(2022), 7, Seite 9 |h Online-Ressource |w (DE-627)KFL000006440 |w (DE-600)2216923-4 |w (DE-576)306832917 |x 1875-676X |7 nnns |
773 | 1 | 8 | |g volume:18 |g year:2022 |g number:7 |g pages:9 |
856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1573-4129&volume=18&issue=7&spage=710 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
912 | |a ZDB-1-BEJ | ||
912 | |a GBV_KFL | ||
912 | |a FID-PHARM | ||
935 | |i IMPORT_0628_prod_DARH_03 | ||
951 | |a AR | ||
952 | |d 18 |j 2022 |e 7 |h 9 |